image-150-64c8cd514b55a.webp

image-151-64c8cd518a917.webp

group-1000002623-64c8cd4f8d576.webp

image-146-64c8cd50567b2.webp

image-147-64c8cd501e463.webp

image-148-64c8cd50b2c5c.webp

image-149-64c8cd50d627e.webp

BBC-Logo.webp

The-Independent-Logo.webp

Featured in

AI biomarkers, built for real-world impact and clinical trials. Meet us at ASCO 2026 | Booth #IH12.

Qure.ai Recognized Among TIME’s 100 Most Influential Companies of 2025

Qure.ai partners with Microsoft to increase access to its lung cancer detection and management suite in the U.S.

qTrack

In a <a href="https://www.embs.org/pulse/articles/ai-driven-covid-19-tools-to-interpret-quantify-lung-images/">concerted effort</a> to augment the fight against COVID-19, research groups across the globe are harnessing the power of artificial intelligence (AI) to revolutionize radiology. These efforts focus on developing tools that enable comprehensive quantitative analysis of lung images, particularly chest X-rays and computed tomography (CT) scans. 

The approach first noted in Wuhan, China, identifies shared health markers in lung images of COVID-19 patients, and employs AI to delineate the extent of lung involvement and to monitor patient progress.

Companies like <a href="http://qure.ai">Qure.ai</a> and Isometric are at the forefront of this technological leap. Qure.ai has developed AI algorithms that not only identify COVID-19 but also differentiate it from other respiratory illnesses. icometrix's AI-based technology, Young, has been pivotal in interpreting CT scans for signs of the disease.

Maryellen L. Giger, Ph.D., A.N. Pritzker Professor of Radiology at the University of Chicago, sees AI not as a replacement but as a tool to assist radiologists and clinicians in detecting and monitoring COVID-19 more quickly and objectively. These AI-based methods promise unprecedented detail and precision, invaluable in managing this global health crisis.

small_52.webp

thumbnail_52.webp

52.webp

AI-Driven COVID-19 Tools to Interpret, Quantify Lung Images

Artificial Intelligence (AI) has become <a href="https://in.mashable.com/tech/15460/ai-in-heathcare-is-now-more-relevant-than-ever-in-the-battle-against-covid-19">omnipresent in healthcare</a>, evident in commonplace devices like Fitbits that track steps and sleep patterns. 

On a grander scale, Mumbai-based <a href="http://qure.ai">Qure.ai </a>utilizes AI to detect 24 markers in chest X-rays, including indications for COVID-19 infection.

"Over the past three years, we've trained our AI to automatically interpret chest X-rays, discerning unconventional from conventional, and identifying the location of any detected negative health markers- all within a minute," says CEO and Co-Founder Prashant Warier. Qure.ai's algorithm has learned from over 7 million scans to differentiate patterns, explains Rohit Ghosh, founding member at Qure.ai.

Qure.ai's machine learning solution, qXR, is designed to detect pulmonary issues, including diseases like tuberculosis. 

Amidst the global COVID-19 pandemic and testing kit shortage, qXR can rapidly identify and prioritize individuals requiring immediate testing or self-isolation, maximizing resource utilization.

Since its COVID-19 adaptation's launch in March, qXR has been implemented in over 40 locations worldwide, including Mumbai, where the Municipal Corporation has adopted the cost-effective solution to assist frontline healthcare professionals.

small_2-1.webp

thumbnail_2-1.webp

2-1.webp

AI In Heathcare Is Now More Relevant Than Ever In The Battle Against COVID-19

Qure.ai has been pivotal in the global <a href="https://insights.omnia-health.com/artificial-intelligence/how-qureai-fighting-covid-19">COVID-19 response</a>, leveraging its radiology AI solutions to aid screening and disease monitoring. Initially established for tuberculosis screening, Qure.ai adapted its technology for COVID-19 triage and progression monitoring, offering two keys on a subscription basis.

In the early pandemic days, amid a scarcity of PCR test kits, Qure.ai repurposed its AI X-ray solution, qXR, to detect COVID-19. It identified markers like opacity indicative of COVID-19 and delivered a score based on these findings. When case numbers grew, Qure.ai further adapted qXR to help monitor disease progression, quantifying infection extent to assist healthcare providers.

Qure.ai's expertise in optimizing and deploying workflows, alongside its presence in 20 countries, helped in this quick pivot. It has signed agreements for data sharing worldwide to improve its AI models, with more than 7 million scans in its data access.

In addition, Qure.ai repurposed tools for contact tracing and remote patient management, aiding healthcare systems in managing workload and infrastructure. For instance, qScout, originally for TB screening, was retooled to support remote patient monitoring during quarantine.

small_30-1.webp

thumbnail_30-1.webp

30-1.webp

How Qure.ai is fighting COVID-19

In the midst of India's relentless battle against the COVID-19 pandemic, the Action Covid-19 Team (ACT) Grants has emerged as a beacon of hope, delivering over 3.5 million testing kits across eight states. This remarkable achievement is a testament to the power of collaboration and innovation in the face of an unprecedented global health crisis.

Established by a group of venture capital partners and the start-up community, ACT Grants has amassed a substantial fund of Rs 100 crore to support initiatives aimed at combating the spread of the virus. The grant's reach extends to 22 Indian states, where it has forged partnerships with renowned companies such as 1MG, Housejoy, and Healthians. These collaborations have been instrumental in facilitating the collection of over 50,000 samples, showcasing the grant's commitment to expanding testing capabilities and reach.

One of the most notable aspects of ACT Grants' approach is its emphasis on innovation. The partnering companies have pioneered creative solutions to enhance the accessibility and efficiency of testing, such as home sample collection, mobile clinics, and protective booths. These groundbreaking initiatives have not only increased the convenience and safety of testing but have also played a crucial role in identifying and isolating positive cases, thereby curbing the spread of the virus.

In addition to its testing efforts, ACT Grants has also garnered support from Qure.ai, a leading healthcare technology company. Qure.ai has made a significant contribution to the fight against COVID-19 by performing chest scans for over 6,000 patients. These scans have proven invaluable in aiding the detection and treatment of the virus, providing healthcare professionals with critical insights into the progression of the disease and enabling them to make informed decisions regarding patient care.

The impact of ACT Grants extends beyond its immediate partnerships and initiatives. As a coalition of top venture capitalists, founders, and industry veterans, the grant serves as a catalyst for tech-driven solutions to the COVID-19 crisis. By providing substantial funding to promising projects, ACT Grants aims to seed and empower teams that have the potential to create a large-scale impact on the detection, prevention, and eradication of the virus.

Moreover, ACT Grants offers more than just financial support. The coalition recognizes the importance of guidance, mentorship, and resources in ensuring the success of the funded initiatives. By leveraging the expertise and networks of its members, ACT Grants provides the necessary support to help these projects scale and achieve their goals. This holistic approach not only maximizes the impact of the grant but also fosters a culture of innovation and collaboration within the Indian start-up ecosystem.

The significance of ACT Grants' work cannot be overstated. In a country as vast and diverse as India, the challenges posed by the COVID-19 pandemic are immense. By focusing on expanding testing capabilities, promoting innovation, and supporting tech-driven solutions, ACT Grants is making a tangible difference in the fight against the virus. The grant's partnerships with companies like 1MG, Housejoy, Healthians, and Qure.ai demonstrate the power of collective action and highlight the critical role that the private sector can play in addressing public health crises.

As India continues to grapple with the ongoing pandemic, initiatives like ACT Grants offer hope and inspiration. By bringing together the brightest minds and most innovative companies, the grant is not only helping to mitigate the immediate impact of the virus but also laying the foundation for a more resilient and prepared healthcare system in the future.

The Action Covid-19 Team (ACT) Grants' delivery of over 3.5 million testing kits across eight states is a remarkable achievement that showcases the power of collaboration, innovation, and tech-driven solutions in the fight against COVID-19. Through its partnerships, funding, and support, ACT Grants is making a significant contribution to India's ongoing battle against the pandemic, offering a glimmer of hope in these challenging times.

small_22-1.webp

thumbnail_22-1.webp

22-1.webp

Start-up community helps in COVID-19 testing; supplies over 3.5 million kits

<a href="https://www.forbes.com/sites/markminevich/2020/06/25/15-companies-that-are-saving-the-world-from-covid-19/?sh=3d0ac1455986">Artificial Intelligence (AI) companies</a> globally are stepping up their game to combat the COVID-19 pandemic. One notable company is Airspace Systems, which has released software that monitors social distancing and face-mask compliance without using facial recognition.

Another trailblazer, BlueDot, developed outbreak risk software that alerted customers about the unusual pneumonia cases in Wuhan, China, nine days before WHO's first warnings. Also, AIDoc has received US FDA approval for its CT scanning capabilities that detect and prioritize incidental CT findings related to COVID-19.

Furthermore, Diagnostic Robotics has developed a digital triage system enabling swift containment measures. At the same time, ZOE has partnered with researchers to create an AI diagnostic tool predicting the likelihood of having COVID-19 based on symptoms. Benevolent AI used automated language tools in the pharmaceutical sector to identify potential drugs for treating COVID-19.

Meanwhile, Traces uses AI to trace the coronavirus through non-face physical traits. Cotiviti's Covid-19 Outbreak Tracker predicts potential hidden hotspots. Apixio's AI analyzes unstructured medical data for risk adjustment, and Insilico is using AI to design molecules targeting the viral protein of COVID-19. Lastly, Qure.ai's chest x-ray product, qXR, received CE certification for detecting common lung health markers, including COVID-induced pneumonia.

small_12-1.webp

thumbnail_12-1.webp

12-1.webp

Companies That Are Saving The World From Covid-19

To counter the chronic shortage of radiologists in populous countries like India, Qure.ai, a start-up founded in 2016 by Prashant Warier and Dr. Pooja Rao, is harnessing the power of <a href="https://www.entrepreneur.com/en-in/technology/this-indian-start-up-is-using-ai-to-monitor-covid-19/351294">artificial intelligence (AI) </a>to interpret radiology scans accurately. Utilizing a database of over seven million scans, their AI can evaluate images within seconds.

The company recently modified its algorithms to detect 19 chest markers, including the novel Coronavirus progression within a patient. This solution, called qXR, analyzes a chest X-ray in a minute, helping healthcare providers in areas like India prioritize patients who need immediate attention, relieving pressure on healthcare infrastructures and costs.

The software quantifies lung damage to generate a COVID-19 score indicating whether a patient is high-, medium-, or low-risk for COVID-19. Presently deployed in seven countries, qXR can determine who needs a swab test and could aid in developing therapeutic approaches to fight the disease.

Qure.ai also offers qScout, a chatbot that remotely monitors patients' symptoms and suggests future actions. From 8-10 sites a year ago, the company operates in over 70 locations across more than 25 countries.

small_5-1.webp

thumbnail_5-1.webp

5-1.webp

This Indian Start-Up Is Using AI To Monitor COVID-19 Progression Inside Patients

In response to the urgent needs of clinicians battling COVID-19, Qure.ai has quickly repurposed its AI tools to interpret lung scans. The company's chest X-ray tool, qXR, uses data from 2.5 million scans to detect lung markers for disease, with recent updates enabling it to provide a COVID-19 risk score.

Chiranjiv Singh, Qure.ai’s chief commercial officer, stated that these AI tools are crucial in assisting critical decisions about patient care, especially where there are testing shortages. The COVID-19 version of the tool is already in use at about 50 global locations, including hospitals in the U.K., India, Italy, and Mexico, and by healthcare workers in Pakistan tracking community cases.

An <a href="https://blogs.nvidia.com/blog/2020/05/28/qure-ai-covid-lung-scans/?ncid=so-twit-58357#cid=ix03_so-twit_en-sg">NVIDIA </a>Inception program member, Qure.ai employs NVIDIA TITAN GPUs on-premises and V100 Tensor Core GPUs through Amazon Web Services for training and inference of its AI models. Qure.ai is seeking FDA clearance for qXR, which already holds the CE mark in Europe.

Its qXR tool provides clinicians with a COVID-19 risk score in under a minute, while quantifying lung lesions. Its efficient, integrated workflow with existing healthcare systems has enabled it to rapidly adapt to the escalating COVID-19 crisis.

small_11.webp

thumbnail_11.webp

11.webp

Qure Helps Clinicians Answer Questions from COVID-19 Lung Scans

As COVID-19 continues to challenge global healthcare systems, Artificial Intelligence (AI) has emerged as a critical technology in the fight against the pandemic. Biotech companies worldwide leverage AI for drug repurposing, clinical trials, data analysis, and patient medical assessments.

AI's capabilities include rapid analysis of large data volumes and predictive modeling, accelerating research and development. Innovators like BenevolentAI are using AI to identify existing drugs that could treat COVID-19, while others, like Iktos and SRI International, are focusing on new drug candidates.

Amid the crisis, AI's ability to rapidly generate actionable information has increased acceptance within the biotech industry. Ronald Dorenbos, the founder of <a href="https://www.genengnews.com/gen-edge/covid-19-puts-spotlight-on-artificial-intelligence/">BioFrontline</a>, highlights the diminishing conservatism towards AI. At the same time, Russ Altman of Stanford Institute underscores the potential of machine learning in drug interaction prediction and 3D structure modeling.

India-based Qure.ai's 'AI-Powered Pandemic Response' provides tools for screening chest X-rays and mapping COVID-19 hotspots. This rapid adoption and application of AI can potentially reshape the future of healthcare, emphasizing its significance in treating and controlling pandemics.

small_11-1.webp

thumbnail_11-1.webp

11-1.webp

COVID-19 Puts Spotlight on Artificial Intelligence

<a href="https://www.theboltonnews.co.uk/news/18433436.radiologist-reveals-ai-helping-royal-bolton-hospital-fight-coronavirus/">Royal Bolton Hospital</a> in the UK is harnessing artificial intelligence (AI) in a groundbreaking approach to monitor and diagnose COVID-19 infections, using chest X-rays to track the progression of the disease. The hospital, the first in the UK to adopt this method, is employing Qure.ai's advanced diagnostic software.

According to Dr. Rizwan Malik, this technology expedites physicians' decision-making processes regarding treatment, providing objective, real-time data on lung damage and other health parameters. This additional layer of information can help indicate a patient's COVID-19 risk level based on the extent of lung damage.

The AI-assisted process bolsters the physician's diagnostic capability, providing immediate insights but does not substitute their medical expertise. It supports a more thorough diagnosis than a blood test or swab could reveal about lung health.

AI's application isn't limited to COVID-19 alone. It's also been successfully used to detect tuberculosis, cancer, and pneumonia and can be repurposed post-pandemic. Dr. Malik expressed optimism regarding this integration of AI into their team, emphasizing its ability to provide the proper care amid the ongoing global health crisis.

small_19-1.webp

thumbnail_19-1.webp

19-1.webp

Radiologist reveals how AI is helping Royal Bolton Hospital to fight coronavirus

Qure.ai's AI-powered tool, qXR, has successfully been repurposed to aid in detecting and monitoring COVID-19 progression using chest X-rays (CXRs). <a href="https://thehealthcareblog.com/blog/2020/05/07/can-ai-and-radiographs-help-in-resource-poor-areas-in-the-fight-against-covid-19/">This advanced technology</a> has been validated on a test set of 11,479 CXRs, including 515 PCR-confirmed COVID-19 cases, with an area under the curve (AUC) of 0.9, making it a promising tool in triage and ongoing monitoring of infected patients.

The tool is currently in use at over 28 global sites, where it assists in patient management amid an overwhelming demand for diagnostic resources. Apart from detecting the virus, qXR also uniquely quantifies the region affected by the infection, allowing for better monitoring of disease progression and response to treatment.

With the potential to complement existing PCR tests, qXR provides a valuable tool in settings with limited diagnostic resources. The AI-powered device can rapidly and extensively support population screening, especially when clinical suspicion of COVID-19 is high. As the world races to contain the virus, AI advancements like qXR could prove instrumental in managing the pandemic and relieving pressure on healthcare systems.

thumbnail_27.webp

27.webp

Can AI and radiographs help in resource-poor areas for the fight against COVID-19?

As the world grapples with the ongoing Covid-19 pandemic, <a href="https://www.bbc.com/news/business-52483082">artificial intelligence (AI) tools are being rapidly adopted</a> and tested worldwide. The AI algorithm, developed by Axial AI, has been instrumental in analyzing CT scans, helping physicians in Wuhan, China, ascertain the severity of viral pneumonia in patients. Currently being trialed in a Malaysian hospital, the tool has offered significant potential for tracking patients' progress.

Meanwhile, in the UK, NHS hospitals are starting to roll out AI for quicker interpretation of chest X-rays. At the Royal Bolton Hospital, an AI system trained on more than 2.5 million X-rays has been employed, assisting clinicians in making critical decisions about patient care. The system, developed by Qure.ai, is entirely housed within the hospital's network, ensuring data privacy.

As these tools emerge, calls for thorough assessment via randomized trials are increasing. While AI has the potential to expedite analysis and treatment plans, experts stress the importance of verifying the reliability and effectiveness of these technologies, as patient lives are at stake.

small_15-1.webp

thumbnail_15-1.webp

15-1.webp

The groundbreaking way to search lungs for signs of Covid-19

AI health tech company Qure.ai has made a significant stride in its mission to revolutionize healthcare by partnering with Bolton NHS Foundation Trust to deploy its cutting-edge COVID-19 monitoring software. This groundbreaking collaboration, the first of its kind in the U.K., marks a crucial step towards harnessing the power of artificial intelligence to combat the ongoing pandemic and improve patient outcomes.

Qure.ai's innovative software is designed to interpret the progression of COVID-19 through the analysis of chest X-rays, providing invaluable quantitative data in less than a minute. This rapid and accurate assessment enables clinicians to classify patients into priority categories based on the severity of their condition, allowing for more effective monitoring of disease progression and targeted allocation of medical resources.

The potential impact of this technology on patient care cannot be overstated. By aligning clinical signs with radiological images, Qure.ai's software offers a comprehensive view of a patient's condition, empowering clinicians to make more informed treatment decisions. Prashant Warier, CEO and cofounder of Qure.ai, emphasizes the significance of this capability, stating that it could potentially enhance patient treatment decisions and optimize clinical outcomes.

While the software is not intended to replace the expertise and judgment of clinicians, it serves as an additional layer of valuable data to support their decision-making process. By providing objective and quantifiable insights, Qure.ai's technology complements the skills and experience of healthcare professionals, enabling them to deliver more personalized and effective care to COVID-19 patients.

The collaboration between Qure.ai and Bolton NHS Foundation Trust is a testament to the growing recognition of the transformative potential of AI in healthcare. With the software already being utilized at 40 sites worldwide, this partnership presents Qure.ai with a unique opportunity to showcase its capabilities within the U.K. healthcare system, which is known for its commitment to innovation and excellence in patient care.

The deployment of Qure.ai's COVID-19 monitoring software at Bolton NHS Foundation Trust is expected to yield valuable insights and learnings that can inform the broader adoption of AI-powered solutions in the fight against the pandemic. By demonstrating the tangible benefits of this technology in a real-world setting, Qure.ai aims to inspire further collaborations and drive the widespread integration of AI in healthcare delivery.

Moreover, the partnership highlights the importance of collaboration between technology companies and healthcare providers in addressing the complex challenges posed by COVID-19. By bringing together the expertise of Qure.ai's team of data scientists, engineers, and medical professionals with the clinical knowledge and experience of Bolton NHS Foundation Trust, this collaboration exemplifies the power of interdisciplinary collaboration in driving innovation and improving patient outcomes.

As the world continues to grapple with the unprecedented challenges of the COVID-19 pandemic, the adoption of AI-powered solutions like Qure.ai's monitoring software offers a glimmer of hope in the quest for more effective and efficient healthcare delivery. By leveraging the power of artificial intelligence to support clinicians in their decision-making and optimize patient care, Qure.ai is at the forefront of a new era in healthcare, one that promises to transform the way we diagnose, treat, and manage diseases.

The partnership between Qure.ai and Bolton NHS Foundation Trust represents a significant milestone in the integration of AI in healthcare, particularly in the context of the COVID-19 pandemic. By deploying its cutting-edge monitoring software, Qure.ai is not only demonstrating the immense potential of AI in enhancing patient care but also setting the stage for further collaborations and innovations in the U.K. healthcare system and beyond. As we look to the future, it is clear that AI will play an increasingly crucial role in shaping the landscape of healthcare delivery, and Qure.ai is poised to be at the forefront of this transformative journey.

Qure.ai Deploys AI Radiology Software In The Fight Against COVID-19

<a href="https://www.forbesindia.com/article/coronavirus/ventures-versus-the-virus-7-indian-startups-fighting-the-pandemic/58989/1">Indian startups</a> exhibit resilience and adaptability amidst the widening coronavirus crisis, characterized as a black swan event with severe global repercussions. Gurugram's AI-focused startup has repurposed its technology for prison monitoring, enabling it to recognize coughing patients on mobile phones, providing a unique solution for hospitals short on staff.

Similarly, Asimov Robotics from Kerala has reoriented its services to assist in healthcare. Its creation, the Karmi-bot, delivers meals and medication to patients, minimizing human contact and potential virus transmission. The robot, programmed to follow a sequence of beds, provides services while ensuring patient interaction through a screen interface.

A Mumbai-based sanitary product manufacturer, identifying the shared raw materials between their products and surgical masks, shifted their production to aid in mask shortages.

Qure.ai, an AI and machine learning-based startup, utilized its pre-existing X-ray analysis software to aid in preliminary COVID-19 testing. The system is being proposed for use in mobile vans for door-to-door testing.

Despite the pandemic's challenges, Indian startups are navigating the crisis with innovative solutions and strategies.

small_9-2.webp

thumbnail_9-2.webp

9-2.webp

Ventures versus the virus 7 Indian startups fighting the pandemic

The COVID-19 pandemic has brought about a significant shift in the healthcare industry, with artificial intelligence (AI) taking center stage in assisting overworked healthcare professionals, particularly radiologists. The adoption of AI-based tools has seen a remarkable surge during this challenging period, proving to be a valuable asset in streamlining radiology workflows and improving patient care.

Rizwan Malik, the lead radiologist at the Royal Bolton Hospital, recognized the immense potential of AI in radiology and took proactive steps to incorporate these cutting-edge tools into his department's operations. Malik's vision was to harness the power of AI to reduce patients' wait times and enhance the efficiency of radiology services. To achieve this goal, he initiated a trial to evaluate the effectiveness of qXR, an AI-powered solution developed by Qure.ai, a Mumbai-based firm specializing in healthcare technology.

The qXR tool, designed to provide second opinions on chest X-rays, showed promising results in its initial implementation. However, as the COVID-19 pandemic swept across the United Kingdom, the trial took on a new level of urgency. Malik and his team quickly adapted qXR to detect COVID-induced pneumonia, a critical development that allowed radiologists to triage patients more effectively amidst the shortage of PCR tests. This swift adaptation of AI technology demonstrated the flexibility and responsiveness of these tools in the face of unprecedented challenges.

The success of qXR in the Royal Bolton Hospital is just one example of how AI is transforming healthcare practices worldwide. As healthcare facilities grapple with the overwhelming demands of the pandemic, AI-based solutions have emerged as a lifeline, enabling healthcare professionals to make more informed decisions, streamline workflows, and provide timely care to patients in need.

However, the rapid adoption of AI in healthcare during the pandemic has also raised concerns among experts. The urgency to deploy AI tools quickly has led to the risk of using unvetted or insufficiently tested solutions, which could potentially compromise patient safety. It is crucial for healthcare organizations to exercise caution and due diligence when implementing AI technologies, ensuring that they have undergone rigorous validation and meet the highest standards of accuracy and reliability.

Despite these challenges, the COVID-19 pandemic has undeniably served as a catalyst for the widespread adoption of AI in healthcare. The crisis has highlighted the immense potential of AI in augmenting human expertise, optimizing resource allocation, and improving patient outcomes. For AI firms operating in the healthcare sector, this accelerated adoption has opened up unprecedented opportunities for growth and innovation.

As the world continues to navigate the complexities of the pandemic, the role of AI in healthcare is expected to expand further. The lessons learned from the rapid deployment of AI tools during this crisis will shape the future of healthcare delivery, paving the way for more sophisticated and integrated AI solutions. Healthcare organizations and AI firms must work together to ensure that the adoption of AI is guided by principles of safety, transparency, and ethical considerations.

The COVID-19 pandemic has served as a turning point for AI adoption in healthcare, particularly in the field of radiology. The success stories, like that of the Royal Bolton Hospital and Qure.ai's qXR tool, demonstrate the transformative potential of AI in enhancing patient care and supporting healthcare professionals during challenging times. As we move forward, it is essential to strike a balance between the rapid adoption of AI and the need for thorough validation and oversight, ensuring that the benefits of these technologies are realized while prioritizing patient safety and well-being.

small_7-1.webp

thumbnail_7-1.webp

7-1.webp

Doctors are using AI to triage covid-19 patients. The tools may be here to stay

Qure.ai has confirmed its innovative diagnostic software deployment at <a href="https://www.mobihealthnews.com/news/bolton-nhs-partners-qureai-monitoring-covid-19-patients">Bolton NHS Foundation Trust in the U.K. </a>

The software expedites and automates the interpretation of chest X-rays for COVID-19, simplifying the tracking of the virus's progression for healthcare workers.

Bolton NHS Foundation Trust, which provides patient care at the Royal Bolton Hospital and other health facilities, will use Qure.ai's solution, qXR. 

This CE-certified, automated chest X-ray interpretation tool can detect findings indicative of COVID-19 and quantify the infection volume, addressing the time-consuming challenge of tracking the virus's spread in patients' lungs.

The deployment comes as tech companies worldwide develop solutions to support healthcare practitioners during the pandemic. U.S. vendors Thirona and Delft Imaging introduced CAD4COVID, an A.I. tool that analyzes X-ray images to aid healthcare specialists, and China's Ping An rolled out its COVID-19 innovative image-reading system.

In February, Qure.ai secured $16M in funding led by Sequoia India to facilitate geographical and product expansion and regulatory clearances.

Fiona Noden, Chief Executive of Bolton NHS Foundation Trust, applauded the incorporation of the latest technology in their fight against COVID-19. 

At the same time, Prashant Warier, CEO and Co-Founder of Qure.ai, highlighted the tool's ability to localize lesions, providing a COVID-19 score for prioritizing patients and quantifying disease progression.

small_26-2.webp

thumbnail_26-2.webp

26-2.webp

 Bolton NHS partners with Qure.ai for monitoring of COVID-19 patients

The apex committee for COVID-19 response and management in <a href="https://www.forbesmiddleeast.com/preview/blogs/omans-ministry-of-health-launches-tarassud?hash=U2FsdGVkX1+a4eyXxAknHg463WcrmWAIpU9+3aGT8CQSAF2jPitYhpnKp3wRaQmF">Oman</a> has launched Tarassud+, a new advanced health monitoring platform. This was announced in collaboration with the Ministry of Interior and Technology and Communication. The venue, an upgrade of the current Tarassud system, utilizes artificial intelligence (AI) to track, diagnose, and follow up on the health of individuals infected with COVID-19 or under quarantine.

Two primary systems make up the Tarassud+ platform. The first is qScout, a contact monitoring and remote triaging program developed by Qure.ai and Al Burkan Company. This AI-powered platform allows for daily monitoring and prioritization of COVID-19 cases, reducing the burden on healthcare facilities.

The second is hMushrif, a medical supervision system developed by eMushrif. It tracks quarantined individuals using a mobile application and a wearable bracelet. The bracelet reports location data and alerts authorities in case of non-compliance with quarantine rules. The bracelet also interfaces with a facial recognition system to automatically identify quarantined individuals.

The system is also integrated with the initial Tarassud system, allowing it to monitor all COVID-19 cases across public and private healthcare centers.

Omans Ministry of Health launches Tarassud+

<a href="https://www.path.org/articles/path-fights-covid-19-india/">Amid India's surge in COVID-19 cases, PATH</a>, an international health organization, is joining forces with Qure.ai, a Mumbai-based AI tech company, to bolster the country's response to the pandemic. PATH's mission supports health equity in low-resource communities and emerging markets globally and supports India during this crisis.

Qure.ai has pivoted its existing technologies to tackle the pandemic, developing two essential tools: qXR and qSCOUT. The qXR platform, initially designed to detect tuberculosis, can interpret chest X-rays in about a minute, identifying lung characteristics indicative of COVID-19. qXR has already been deployed in Italy, the Philippines, and Southeast Asia.

Complementing qXR is qSCOUT, a contact tracing app retooled for COVID-19 that aids in patient registration, remote monitoring, and hotspot mapping to optimize supply chain and test kit distribution.

Simultaneously, PATH is aiding in managing travel and case tracking information and strengthening laboratory systems. Through a collaborative approach, PATH and Qure.ai reinforce India's health system in its battle against COVID-19.

small_33-1 (1).webp

thumbnail_33-1 (1).webp

33-1 (1).webp

With technology, information, and staff, PATH fights COVID-19 in India

As the global Covid-19 cases surpass the staggering milestone of 12 million, countries worldwide find themselves grappling with an acute shortage of testing kits. This scarcity has put immense pressure on healthcare systems, forcing them to make difficult decisions about who gets tested and when. In response to this pressing challenge, Qure.ai, a renowned leader in healthcare technology, has pioneered an AI-backed solution that could revolutionize the way testing priorities are determined amidst such scarcity.

The innovative approach introduced by Qure.ai leans on the fundamental principle of medical triaging, a process that involves categorizing patients based on the severity of their illnesses or wounds. Triaging has long been a cornerstone of emergency medicine, enabling healthcare professionals to make quick and informed decisions about the order in which patients should receive treatment. By applying this principle to the context of Covid-19 testing, Qure.ai aims to streamline the testing process among large populations and identify individuals who require immediate attention.

At the heart of Qure.ai's cutting-edge technology lies the power of artificial intelligence. The company has developed a sophisticated AI algorithm that can interpret X-rays with remarkable accuracy. By analyzing chest X-rays of potential Covid-19 patients, the AI system can detect signs of lung abnormalities associated with the virus, such as ground-glass opacities and consolidations. This information is then used to classify patients into three risk categories: high, medium, and low.

The classification of patients based on their risk level is a game-changer in the face of testing kit shortages. Healthcare professionals can utilize Qure.ai's AI-powered solution to prioritize testing procedures for those who are deemed high-risk, ensuring that the most critical cases receive immediate attention. This targeted approach not only optimizes the use of limited testing resources but also helps identify individuals who may require urgent medical intervention.

Moreover, Qure.ai's solution goes beyond just prioritizing testing. The AI algorithm can also provide valuable insights into the progression of the disease in individual patients. By comparing X-rays taken at different stages of the illness, the system can track changes in lung abnormalities over time, enabling healthcare professionals to monitor patient recovery or deterioration more effectively. This longitudinal assessment can aid in making informed decisions about treatment plans and resource allocation.

The impact of Qure.ai's AI-backed solution extends far beyond the realm of healthcare facilities. By enabling more efficient and targeted testing, the technology can help contain the spread of the virus in communities. Identifying and isolating high-risk individuals early on can break the chain of transmission, reducing the overall burden on healthcare systems and saving countless lives in the process.

As the demand for testing kits continues to outstrip supply, Qure.ai's innovative solution offers a beacon of hope in the fight against Covid-19. By harnessing the power of AI to interpret X-rays and prioritize testing procedures, the company is providing healthcare professionals with a valuable tool to navigate the challenges posed by resource scarcity. The efficient utilization of testing kits, coupled with the ability to identify high-risk patients promptly, can make a significant difference in the battle against this global pandemic.

Qure.ai's AI-backed solution for Covid-19 testing prioritization is a testament to the transformative potential of technology in healthcare. As countries worldwide continue to grapple with the unprecedented challenges posed by the virus, innovative approaches like those pioneered by Qure.ai will be instrumental in saving lives and mitigating the impact of the pandemic. By embracing the power of AI and adapting to the changing landscape of healthcare, we can work towards a future where no one is left behind in the fight against Covid-19.

small_13.webp

thumbnail_13.webp

13.webp

How Qure.ai is helping Italian doctors test Covid-19 patients

In response to the ongoing pandemic, <a href="https://inc42.com/buzz/startupsvscovid19-niti-aayog-invites-eight-startups-to-be-part-of-covid-19-committee/">India's central government</a> is working diligently to bolster the country's healthcare infrastructure. They have formed a committee, led by NITI Aayog CEO Amitabh Kant, to collaborate with private companies and startups to produce health and personal protection equipment (PPE).

The committee has hosted six meetings with various organizations since its inception on March 3. These organizations, consisting of startups, industry associations, and civil society groups, are working together to devise solutions to the healthcare challenges posed by the pandemic.

The startups involved range from AgVa, developing compact ventilators, to Qure.ai, which works on solutions to interpret chest X-rays automatically. The committee's efforts extend beyond equipment production, as the government seeks to enhance the security of its Aarogya Setu app, a tool used to keep users' data safe during the crisis.

By fostering collaboration and innovation, the committee strives to strengthen India's healthcare system to manage current and future health crises better.

small_36-1.webp

thumbnail_36-1.webp

36-1.webp

Startups vs covid19 Niti Aayog Invites Eight Startups To Be Part Of Covid 19 Committee

As the COVID-19 pandemic continues, the role of artificial intelligence (AI) in global health efforts becomes increasingly crucial. However, the <a href="https://www.zdnet.com/article/ai-runs-smack-up-against-a-big-data-problem-in-covid-19-diagnosis/">lack of readily accessible, unified data is hampering advancements</a>. AI has shown potential in diagnosing COVID-19 through X-ray or computed tomography (CT) scans, providing quicker results than traditional genetic testing. This has prompted the development of deep-learning neural networks to analyze these scans and streamline the radiologist's workflow.

Success stories have emerged, particularly in China, with firms like Infervision, Alibaba, and Deepwise Technology achieving notable strides in AI diagnoses. However, the lack of data accessibility and the uniqueness of COVID-19 as a disease pose significant challenges. As Wei Xu from Tsinghua University states, the deployment of these technologies has been slow, despite their potential.

Creating an AI system that efficiently identifies COVID-19-specific scan anomalies requires extensive data and collaboration with experienced physicians. The pipeline developed by Xu's team utilizes two deep learning networks refined over many years, the ResNet-50 and UNet++, to effectively differentiate COVID-19 features from other conditions. Despite their efforts, sourcing additional data for further refinement remains a significant hurdle.

small_8-1.webp

thumbnail_8-1.webp

8-1.webp

AI runs smack up against a big data problem in COVID-19 diagnosis

Qure.ai has <a href="https://www.med-technews.com/news/ai-solutions-player-to-help-monitor-covid-19-patients-in-ita/">introduced</a> an automated chest X-ray solution, qXR, which can swiftly interpret lung scans from COVID-19 patients, quantifying the extent of their lung infection. This technological advancement alleviates pressure from inundated radiologists, who previously had to quantify the infection levels—a time-consuming process manually.

The AI-powered tool can detect indications of COVID-19, such as ground-glass opacities and consolidation markers. It also identifies tuberculosis, chronic obstructive pulmonary diseases, lung malignancies, and medical emergencies like lung collapses and cardiac disorders. Additionally, the system localizes lesions and measures infection volumes.

CEO and co-founder of Qure.ai, Prashant Warier, believes using qXR can objectively monitor disease progression in COVID-19 patients and their response to different therapeutic approaches. "Our expertise tackling Tuberculosis has enabled us to develop AI solutions to combat the COVID-19 pandemic," said Warier. He asserts that their innovative algorithm can help ease the workload of hospital staff and help devise the best treatment options for patients at various COVID-19 stages.

small_50.webp

thumbnail_50.webp

50.webp

AI-solutions player to help monitor COVID-19 patients in Italy

Qure.ai, a pioneer in artificial intelligence (AI) solutions for radiology, <a href="https://www.dotmed.com/news/story/50661">is set to collaborate with Italy's San Raffaele university hospital</a> to enhance COVID-19 patient monitoring using its automated chest X-ray solution, qXR. This solution interprets lung scans within seconds, determining the extent of lung damage due to the virus.

The groundbreaking AI technology eases the workload of overstretched clinicians, offering a consistent and efficient method to monitor disease progression. qXR's capabilities extend beyond COVID-19 detection, identifying conditions such as tuberculosis, chronic obstructive pulmonary diseases, lung malignancies, and medical emergencies.

"Through our AI solution, we offer an objective approach to monitoring COVID-19 disease progression and response to various treatments," said Prashant Warier, CEO and Co-Founder of Qure.ai. He further underscored the value of their algorithm in managing the pandemic by easing the healthcare staff's workload and facilitating new therapeutic discoveries.

As one of the hardest-hit nations by the pandemic, Italy stands to benefit significantly from this AI intervention, offering much-needed relief to its strained healthcare infrastructure.

News and Press